Perennial Allergic Rhinitis - Pipeline Insight, 2024

This Perennial Allergic Rhinitis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Perennial Allergic Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Perennial Allergic Rhinitis Understanding

Perennial Allergic Rhinitis: Overview

Perennial rhinitis may be defined clinically as an inflammatory condition of the nose characterised by nasal obstruction, sneezing, itching, or rhinorrhoea, occurring for an hour or more on most days throughout the year. Perennial allergic rhinitis can be more difficult to diagnose than seasonal allergy, particularly if the patient presents with secondary symptoms of sinusitis and a “permanent cold.” The most common allergen to account for perennial allergic symptoms is the house dust mite (Dermatophagoides pteronyssinus). Other frequent causes are animals: particularly cats, dogs, and horses. Not everyone with perennial allergic rhinitis has been officially diagnosed, so it's not clear how many people actually have the condition. Some research suggests that up to 23% of the population experiences perennial allergic rhinitis. Perennial allergic rhinitis is associated with other conditions as well. Asthma is one of the most common. Nasal inflammation is the the most common symptom of perennial allergic rhinitis. Perennial allergic rhinitis can be diagnosed by a primary care healthcare provider or an allergist.

Perennial Allergic Rhinitis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Perennial Allergic Rhinitis pipeline landscape is provided which includes the disease overview and Perennial Allergic Rhinitis treatment guidelines. The assessment part of the report embraces, in depth Perennial Allergic Rhinitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Perennial Allergic Rhinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Perennial Allergic Rhinitis. The therapies under development are focused on novel approaches to treat/improve Perennial Allergic Rhinitis.

Perennial Allergic Rhinitis Emerging Drugs

MM09-MG01: Inmunotek
Inmunotek is developing a subcutaneously administered immunotherapy product MM 09, containing biological extracts of house dust mite, designated as M 601 (MM09-MG01). A Phase III Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and allergic rhinitis/rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and grass pollen has been initiated..

Perennial Allergic Rhinitis: Therapeutic Assessment

This segment of the report provides insights about the Perennial Allergic Rhinitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Perennial Allergic Rhinitis

There are approx. 5+ key companies which are developing the therapies Perennial Allergic Rhinitis. The companies which have their Perennial Allergic Rhinitis drug candidates in the most advanced stage, i.e phase II include Hanmi Pharmaceutical

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Perennial Allergic Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Perennial Allergic Rhinitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Perennial Allergic Rhinitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Perennial Allergic Rhinitis drugs.

Perennial Allergic Rhinitis Report Insights

• Perennial Allergic Rhinitis Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Perennial Allergic Rhinitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Perennial Allergic Rhinitis drugs?
• How many Perennial Allergic Rhinitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Perennial Allergic Rhinitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Perennial Allergic Rhinitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Perennial Allergic Rhinitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Hanmi Pharmaceutical PIII
• Lyra Therapeutics
• Inmunotek

Key Products

• Levocetirizine/montelukast
• Mometasone eluting resorbable scaffold
• MM09-MG01